z-logo
open-access-imgOpen Access
Hyperglycemia, a Neglected Factor during Cancer Progression
Author(s) -
Wanxing Duan,
Xin Shen,
Jianjun Lei,
Qinhong Xu,
Yongtian Yu,
Rong Li,
Erxi Wu,
Qingyong Ma
Publication year - 2014
Publication title -
biomed research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 126
eISSN - 2314-6141
pISSN - 2314-6133
DOI - 10.1155/2014/461917
Subject(s) - cancer , medicine , insulin resistance , carcinogenesis , diabetes mellitus , oncology , tumor progression , cancer cell , incidence (geometry) , drug resistance , cancer incidence , type 2 diabetes , bioinformatics , cancer research , endocrinology , biology , physics , microbiology and biotechnology , optics
Recent evidence from large cohort studies suggests that there exists a higher cancer incidence in people with type 2 diabetes (DM2). However, to date, the potential reasons for this association remain unclear. Hyperglycemia, the most important feature of diabetes, may be responsible for the excess glucose supply for these glucose-hungry cells, and it contributes to apoptosis resistance, oncogenesis, and tumor cell resistance to chemotherapy. Considering associations between diabetes and malignancies, the effect of hyperglycemia on cancer progression in cancer patients with abnormal blood glucose should not be neglected. In this paper, we describe the role that hyperglycemia plays in cancer progression and treatment and illustrate that hyperglycemia may contribute to a more malignant phenotype of cancer cells and lead to drug resistance. Therefore, controlling hyperglycemia may have important therapeutic implications in cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom